{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T06:01:37Z","timestamp":1774072897981,"version":"3.50.1"},"reference-count":64,"publisher":"American Association for Cancer Research (AACR)","issue":"9","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background: Because of the faltering sensitivity and\/or specificity, urine-based assays currently have a limited role in the management of patients with bladder cancer. The aim of this study was to externally validate our previously reported protein biomarker panel from multiple sites in the United States and Europe.<\/jats:p>\n                  <jats:p>Methods: This multicenter external validation study included a total of 320 subjects (bladder cancer = 183). The 10 biomarkers (IL8, MMP9, MMP10, SERPINA1, VEGFA, ANG, CA9, APOE, SDC1, and SERPINE1) were measured using commercial ELISA assays in an external laboratory. The diagnostic performance of the biomarker panel was assessed using receiver operator curves (ROC) and descriptive statistical values.<\/jats:p>\n                  <jats:p>Results: Utilizing the combination of all 10 biomarkers, the area under the ROC for the diagnostic panel was noted to be 0.847 (95% confidence interval, 0.796\u20130.899), outperforming any single biomarker. The multiplex assay at optimal cutoff value achieved an overall sensitivity of 0.79, specificity of 0.79, positive prediction value of 0.73, and negative prediction value of 0.84 for bladder cancer classification. Sensitivity values of the diagnostic panel for high-grade bladder cancer, low-grade bladder cancer, muscle invasive bladder cancer, and non-muscle invasive bladder cancer were 0.81, 0.90, 0.95, and 0.77, respectively.<\/jats:p>\n                  <jats:p>Conclusions: Urinary levels of the biomarker panel enabled discrimination of patients with bladder cancer and controls, and the levels of biomarker subsets were associated with advancing tumor grade and stage.<\/jats:p>\n                  <jats:p>Impact: If proven to be reliable, urinary diagnostic biomarker assays can detect bladder cancer in a timely manner such that the patient can expect improvements in overall survival and quality of life. Cancer Epidemiol Biomarkers Prev; 23(9); 1804\u201312. \u00a92014 AACR.<\/jats:p>","DOI":"10.1158\/1055-9965.epi-14-0029","type":"journal-article","created":{"date-parts":[[2014,6,12]],"date-time":"2014-06-12T02:32:36Z","timestamp":1402540356000},"page":"1804-1812","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["External Validation of a Multiplex Urinary Protein Panel for the Detection of Bladder Cancer in a Multicenter Cohort"],"prefix":"10.1158","volume":"23","author":[{"given":"Li-Mei","family":"Chen","sequence":"first","affiliation":[{"name":"1Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida."}]},{"given":"Myron","family":"Chang","sequence":"additional","affiliation":[{"name":"2Department of Biostatistics, The University of Florida, Gainesville, Florida."}]},{"given":"Yunfeng","family":"Dai","sequence":"additional","affiliation":[{"name":"2Department of Biostatistics, The University of Florida, Gainesville, Florida."}]},{"given":"Karl X.","family":"Chai","sequence":"additional","affiliation":[{"name":"1Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida."}]},{"given":"Lars","family":"Dyrskj\u00f8t","sequence":"additional","affiliation":[{"name":"3Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark."}]},{"given":"Marta","family":"Sanchez-Carbayo","sequence":"additional","affiliation":[{"name":"4Bladder Cancer Group, Proteomics Unit, Bizkaia, Spain."}]},{"given":"Tibor","family":"Szarvas","sequence":"additional","affiliation":[{"name":"5Department of Urology, University Hospital Duisburg-Essen, Essen, Germany."}]},{"given":"Ellen C.","family":"Zwarthoff","sequence":"additional","affiliation":[{"name":"6Department of Pathology, Erasmus MC, Rotterdam, the Netherlands."}]},{"given":"Vinata","family":"Lokeshwar","sequence":"additional","affiliation":[{"name":"7Department of Urology, University of Miami Miller School of Medicine, Miami, Florida."},{"name":"8Department of Cell Biology, University of Miami Miller School of Medicine, Miami, Florida."}]},{"given":"Carmen","family":"Jeronimo","sequence":"additional","affiliation":[{"name":"9Cancer Epigenetics Group, Research Center Portuguese Oncology Institute, Porto, Portugal."},{"name":"10Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal."}]},{"given":"Alexander S.","family":"Parker","sequence":"additional","affiliation":[{"name":"11Department of Urology, Mayo Clinic Florida, Jacksonville, Florida."}]},{"given":"Shanti","family":"Ross","sequence":"additional","affiliation":[{"name":"12Cancer Research Institute, MD Anderson Cancer Center, Orlando, Florida."}]},{"given":"Michael","family":"Borre","sequence":"additional","affiliation":[{"name":"3Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark."}]},{"given":"Torben F.","family":"\u00d8rntoft","sequence":"additional","affiliation":[{"name":"3Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark."}]},{"given":"Tobias","family":"Jaeger","sequence":"additional","affiliation":[{"name":"5Department of Urology, University Hospital Duisburg-Essen, Essen, Germany."}]},{"given":"Willemien","family":"Beukers","sequence":"additional","affiliation":[{"name":"6Department of Pathology, Erasmus MC, Rotterdam, the Netherlands."}]},{"given":"Luis E.","family":"Lopez","sequence":"additional","affiliation":[{"name":"7Department of Urology, University of Miami Miller School of Medicine, Miami, Florida."},{"name":"8Department of Cell Biology, University of Miami Miller School of Medicine, Miami, Florida."}]},{"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[{"name":"9Cancer Epigenetics Group, Research Center Portuguese Oncology Institute, Porto, Portugal."},{"name":"10Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal."}]},{"given":"Paul R.","family":"Young","sequence":"additional","affiliation":[{"name":"11Department of Urology, Mayo Clinic Florida, Jacksonville, Florida."}]},{"given":"Virginia","family":"Urquidi","sequence":"additional","affiliation":[{"name":"12Cancer Research Institute, MD Anderson Cancer Center, Orlando, Florida."},{"name":"13Nonagen Bioscience Corp., Jacksonville, Florida."}]},{"given":"Steve","family":"Goodison","sequence":"additional","affiliation":[{"name":"12Cancer Research Institute, MD Anderson Cancer Center, Orlando, Florida."},{"name":"13Nonagen Bioscience Corp., Jacksonville, Florida."},{"name":"14Department of Health Sciences Research, Mayo Clinic, Jacksonville, Florida."}]},{"given":"Charles J.","family":"Rosser","sequence":"additional","affiliation":[{"name":"12Cancer Research Institute, MD Anderson Cancer Center, Orlando, Florida."},{"name":"13Nonagen Bioscience Corp., Jacksonville, Florida."},{"name":"15University of Hawaii, Honolulu, Hawaii."}]}],"member":"1086","published-online":{"date-parts":[[2014,9,1]]},"reference":[{"key":"2022060919154217700_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"2022060919154217700_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"2022060919154217700_bib3","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1159\/000020069","article-title":"Epidemiology of bladder cancer","volume":"36","author":"Aben","year":"1999","journal-title":"Eur Urol"},{"key":"2022060919154217700_bib4","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update","volume":"178","author":"Hall","year":"2007","journal-title":"J Urol"},{"key":"2022060919154217700_bib5","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.eururo.2005.03.014","article-title":"Urine markers for bladder cancer surveillance: a systematic review","volume":"47","author":"vanRhijn","year":"2005","journal-title":"Eur Urol"},{"key":"2022060919154217700_bib6","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1158\/1078-0432.CCR-10-3121","article-title":"Urinary glycoprotein biomarker discovery for bladder cancer detection using LC\/MS-MS and label-free quantification","volume":"17","author":"Yang","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022060919154217700_bib7","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1021\/pr0700807","article-title":"Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling","volume":"6","author":"Kreunin","year":"2007","journal-title":"J Proteome Res"},{"key":"2022060919154217700_bib8","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1158\/1055-9965.EPI-12-0428","article-title":"A candidate molecular biomarker panel for the detection of bladder cancer","volume":"21","author":"Urquidi","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022060919154217700_bib9","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/1055-9965.EPI-08-1002","article-title":"Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia","volume":"18","author":"Rosser","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022060919154217700_bib10","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.juro.2012.07.094","article-title":"Diagnostic potential of urinary &lt;alpha&gt;1-antitrypsin and apolipoprotein E in the detection of bladder cancer","volume":"188","author":"Urquidi","year":"2012","journal-title":"J Urol"},{"key":"2022060919154217700_bib11","doi-asserted-by":"crossref","first-page":"e37797","DOI":"10.1371\/journal.pone.0037797","article-title":"CCL18 in a multiplex urine-based assay for the detection of bladder cancer","volume":"7","author":"Urquidi","year":"2012","journal-title":"PLoS ONE"},{"key":"2022060919154217700_bib12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2490-12-12","article-title":"IL-8 as a urinary biomarker for the detection of bladder cancer","volume":"12","author":"Urquidi","year":"2012","journal-title":"BMC Urol"},{"key":"2022060919154217700_bib13","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.urology.2012.01.016","article-title":"Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection","volume":"79","author":"Urquidi","year":"2012","journal-title":"Urology"},{"key":"2022060919154217700_bib14","doi-asserted-by":"crossref","first-page":"e47469","DOI":"10.1371\/journal.pone.0047469","article-title":"A multi-analyte assay for the non-invasive detection of bladder cancer","volume":"7","author":"Goodison","year":"2012","journal-title":"PLoS ONE"},{"key":"2022060919154217700_bib15","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/j.juro.2013.06.011","article-title":"Multiplex protein signature for the detection of bladder cancer in voided urine samples","volume":"190","author":"Rosser","year":"2013","journal-title":"J Urol"},{"key":"2022060919154217700_bib16","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.ajpath.2012.01.023","article-title":"Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer","volume":"180","author":"Fristrup","year":"2012","journal-title":"Am J Pathol"},{"key":"2022060919154217700_bib17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s13277-010-0033-9","article-title":"Galectin-3 expression is associated with bladder cancer progression and clinical outcome","volume":"31","author":"Canesin","year":"2010","journal-title":"Tumour Biol"},{"key":"2022060919154217700_bib18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s12253-010-9320-4","article-title":"Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer","volume":"17","author":"Szarvas","year":"2011","journal-title":"Pathol Oncol Res"},{"key":"2022060919154217700_bib19","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.juro.2012.11.115","article-title":"Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project","volume":"189","author":"Zuiverloon","year":"2013","journal-title":"J Urol"},{"key":"2022060919154217700_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cncr.27661","article-title":"C-X-C chemokine receptor 7: a functionally associated molecular marker for bladder cancer","volume":"119","author":"Yates","year":"2013","journal-title":"Cancer"},{"key":"2022060919154217700_bib21","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.4161\/epi.6.9.16376","article-title":"TCF21 and PCDH17 methylation: an innovative panel of biomarkers for a simultaneous detection of urological cancers","volume":"6","author":"Costa","year":"2011","journal-title":"Epigenetics"},{"key":"2022060919154217700_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.urology.2005.08.064","article-title":"Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers","volume":"66","author":"Lokeshwar","year":"2005","journal-title":"Urology"},{"key":"2022060919154217700_bib23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/fampra\/cmh103","article-title":"Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative","volume":"21","author":"Bossuyt","year":"2004","journal-title":"Fam Pract"},{"key":"2022060919154217700_bib24","doi-asserted-by":"crossref","first-page":"e53354","DOI":"10.1371\/journal.pone.0053354","article-title":"Standardization of diagnostic biomarker concentrations in urine: the hematuria caveat","volume":"7","author":"Reid","year":"2012","journal-title":"PLoS ONE"},{"key":"2022060919154217700_bib25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene Expression Omnibus: NCBI gene expression and hybridization array data repository","volume":"30","author":"Edgar","year":"2002","journal-title":"Nucleic Acids Res"},{"key":"2022060919154217700_bib26","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/bimj.200410135","article-title":"Estimation of the Youden Index and its associated cutoff point","volume":"47","author":"Fluss","year":"2005","journal-title":"Biom J"},{"key":"2022060919154217700_bib27","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/jnci\/djn326","article-title":"Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design","volume":"100","author":"Pepe","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"2022060919154217700_bib28","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.eururo.2007.11.048","article-title":"Photodynamic diagnosis in urology: state-of-the-art","volume":"53","author":"Jocham","year":"2008","journal-title":"Eur Urol"},{"key":"2022060919154217700_bib29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.urology.2006.03.062","article-title":"Clinical model of lifetime cost of treating bladder cancer and associated complications","volume":"68","author":"Avritscher","year":"2006","journal-title":"Urology"},{"key":"2022060919154217700_bib30","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/cncr.22084","article-title":"Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis","volume":"107","author":"Lotan","year":"2006","journal-title":"Cancer"},{"key":"2022060919154217700_bib31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.urolonc.2005.11.025","article-title":"Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis","volume":"24","author":"Svatek","year":"2006","journal-title":"Urol Oncol"},{"key":"2022060919154217700_bib32","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0022-5347(17)35290-4","article-title":"The effects of intraurethrallidocaine anesthetic and patient anxiety on pain perception during cystoscopy","volume":"151","author":"Stein","year":"1994","journal-title":"J Urol"},{"key":"2022060919154217700_bib33","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/jnci\/95.8.588","article-title":"Adherence to surveillance among patients with superficial bladder cancer","volume":"95","author":"Schrag","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2022060919154217700_bib34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2490-9-12","article-title":"Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria","volume":"9","author":"Nakamura","year":"2009","journal-title":"BMC Urol"},{"key":"2022060919154217700_bib35","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/jjco\/hyi244","article-title":"Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer","volume":"36","author":"Kumar","year":"2006","journal-title":"Jpn J Clin Oncol"},{"key":"2022060919154217700_bib36","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0302-2838(02)00006-4","article-title":"Differences between local and review urinary cytology in diagnosis of bladder cancer: an interobserver multicenter analysis","volume":"4","author":"Raitanen","year":"2002","journal-title":"Eur Urol"},{"key":"2022060919154217700_bib37","first-page":"472","article-title":"Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer","volume":"45","author":"Thomas","year":"1999","journal-title":"Clin Chem"},{"key":"2022060919154217700_bib38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1515\/CCLM.2003.018","article-title":"Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)\u2014useful diagnostic tools in the diagnosis of urinary bladder cancer?","volume":"41","author":"Mahnert","year":"2003","journal-title":"Clin Chem Lab Med"},{"key":"2022060919154217700_bib39","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0090-4295(97)00508-6","article-title":"Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group","volume":"50","author":"Ellis","year":"1997","journal-title":"Urology"},{"key":"2022060919154217700_bib40","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0022-5347(05)64659-9","article-title":"Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors","volume":"168","author":"Eissa","year":"2002","journal-title":"J Urol"},{"key":"2022060919154217700_bib41","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0022-5347(01)61899-8","article-title":"Comparison of screening methods in the detection of bladder cancer","volume":"161","author":"Ramakumar","year":"1999","journal-title":"J Urol"},{"key":"2022060919154217700_bib42","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1245\/s10434-012-2561-6","article-title":"Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients","volume":"19","author":"Nguyen","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"2022060919154217700_bib43","doi-asserted-by":"crossref","first-page":"941495","DOI":"10.1155\/2012\/941495","article-title":"Treatment choices based on OncotypeDx in the breast oncology care setting","volume":"2012","author":"Malo","year":"2012","journal-title":"J Cancer Epidemiol"},{"key":"2022060919154217700_bib44","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0022-5347(01)61772-5","article-title":"Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates","volume":"161","author":"Crew","year":"1999","journal-title":"J Urol"},{"key":"2022060919154217700_bib45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3233\/CBM-2007-3601","article-title":"The diagnostic efficacy of urinary TGF-\u03b21 and VEGF in bladder cancer: comparison with voided urine cytology","volume":"3","author":"Eissa","year":"2007","journal-title":"Cancer Biomark"},{"key":"2022060919154217700_bib46","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0090-4295(03)00134-1","article-title":"Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma","volume":"62","author":"Sheryka","year":"2003","journal-title":"Urology"},{"key":"2022060919154217700_bib47","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.eururo.2010.10.008","article-title":"Stress proteins and cytokines are urinary biomarkers for diagnosis and staging of bladder cancer","volume":"59","author":"Margel","year":"2011","journal-title":"Eur Urol"},{"key":"2022060919154217700_bib48","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.eururo.2007.04.006","article-title":"Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine","volume":"52","author":"Eissa","year":"2007","journal-title":"Eur Urol"},{"key":"2022060919154217700_bib49","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1158\/1078-0432.CCR-08-1136","article-title":"Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species","volume":"14","author":"Roy","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022060919154217700_bib50","doi-asserted-by":"crossref","first-page":"298","DOI":"10.4149\/neo_2009_04_29","article-title":"Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract","volume":"56","author":"Hyrsl","year":"2009","journal-title":"Neoplasma"},{"key":"2022060919154217700_bib51","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jprot.2013.04.024","article-title":"Identification of potential bladder cancer markers in urine by abundant-protein depletion coupled with quantitative proteomics","volume":"85","author":"Chen","year":"2013","journal-title":"J Proteomics"},{"key":"2022060919154217700_bib52","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/sj.bjc.6602813","article-title":"Gene expression profiling of noninvasive primary urothelial tumours using microarrays","volume":"93","author":"Aaboe","year":"2005","journal-title":"Br J Cancer"},{"key":"2022060919154217700_bib53","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1078-0432.CCR-07-1672","article-title":"Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder","volume":"14","author":"Holyoake","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022060919154217700_bib54","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1373\/clinchem.2007.091363","article-title":"Detailed technical analysis of urine RNA-based tumor diagnostics reveals ETS2\/urokinase plasminogen activator to be a novel marker for bladder cancer","volume":"53","author":"Hanke","year":"2007","journal-title":"Clin Chem"},{"key":"2022060919154217700_bib55","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1158\/1078-0432.CCR-09-3373","article-title":"Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma","volume":"16","author":"Mengual","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2022060919154217700_bib56","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/S0022-5347(06)00283-7","article-title":"Multiplex polymerase chain reaction for microsatellite analysis of urine sediment cells: a rapid and inexpensive method for diagnosing and monitoring superficial transitional bladder cell carcinoma","volume":"175","author":"Bartoletti","year":"2006","journal-title":"J Urol"},{"key":"2022060919154217700_bib57","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10456-012-9254-4","article-title":"Over-expression of BMP4 inhibits experimental choroidal neovascularization by modulating VEGF and MMP-9","volume":"15","author":"Xu","year":"2012","journal-title":"Angiogenesis"},{"key":"2022060919154217700_bib58","article-title":"Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways","author":"Zhang","year":"2014","journal-title":"BMC Cancer"},{"key":"2022060919154217700_bib59","doi-asserted-by":"crossref","first-page":"6382","DOI":"10.1182\/blood-2011-12-399659","article-title":"Inhibition of PAI-1 induces neutrophil-driven neoangiogenesis and promotes tissue regeneration via production of angiocrine factors in mice","volume":"119","author":"Tashiro","year":"2012","journal-title":"Blood"},{"key":"2022060919154217700_bib60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid, and other diseases","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat Med"},{"key":"2022060919154217700_bib61","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1126\/science.2432664","article-title":"Angiogenic factors","volume":"235","author":"Folkman","year":"1987","journal-title":"Science"},{"key":"2022060919154217700_bib62","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"2022060919154217700_bib63","first-page":"89","article-title":"Tumor interactions with the vasculature: angiogenesis and tumor metastasis","volume":"1032","author":"Blood","year":"1990","journal-title":"Biochem Biophys Acta"},{"key":"2022060919154217700_bib64","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1158\/1055-9965.EPI-14-0035","article-title":"Urinary protein biomarker panel for the detection of recurrent bladder cancer","volume":"23","author":"Rosser","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Cancer Epidemiology, Biomarkers &amp; Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cebp\/article-pdf\/23\/9\/1804\/2279632\/1804.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cebp\/article-pdf\/23\/9\/1804\/2279632\/1804.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T17:39:17Z","timestamp":1654796357000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cebp\/article\/23\/9\/1804\/14085\/External-Validation-of-a-Multiplex-Urinary-Protein"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,1]]},"references-count":64,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,9,1]]},"published-print":{"date-parts":[[2014,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1055-9965.epi-14-0029","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/1055-9965.22435360","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1055-9965.22435357.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1055-9965.22435354","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1055-9965.22435363","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1055-9965.c.6514882.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1055-9965.c.6514882","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1055-9965.22435357","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1055-9965.22435360.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1055-9965.22435363.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1055-9965.22435354.v1","asserted-by":"object"}]},"ISSN":["1055-9965","1538-7755"],"issn-type":[{"value":"1055-9965","type":"print"},{"value":"1538-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,1]]}}}